A step towards development of promising trypanocidal agents: Synthesis, characterization and in vitro biological evaluation of ferrocenyl Mannich base-type derivatives

Synthetic strategies for the incorporation of metallocenes into anti-infective scaffolds

With the rates of infectious diseases and (pan)drug-resistant pathogens constantly increasing, there is a pressing need for the development of new drug candidates. To fight this global health crisis, new medicines should propose improved or novel modes of action. A successful strategy to fight microbial resistance is the incorporation of metallocenes into drug scaffolds. This review aims at encouraging the scientific community to follow this approach by giving an overview of all published synthetic strategies either for the derivatization of anti-infective drug scaffolds with metallocenes or for the de novo synthesis of original metallocenyl anti-infectives. This should facilitate future research as published articles are classified depending on the reaction type that is employed for the incorporation of the metallocenes, namely addition-elimination, condensation, "click" chemistry, cross-coupling, nucleophilic substitution and other methods. Overall, this review exhibits the impressive but somewhat unexploited potential of anti-infective metallocenyl compounds to treat infectious diseases.

Targeting Neglected Tropical Diseases and Malaria: The Therapeutic Promise of Mannich Bases

Neglected tropical diseases (NTDs) and malaria remain significant public health challenges, particularly in resource-limited regions. The search for novel therapeutic agents to combat these diseases is imperative due to emerging drug resistance and limited treatment options. Mannich bases, a class of organic compounds synthesised via the Mannich reaction, exhibit diverse pharmacological properties, including antimicrobial, antimalarial, antiviral, antimycobacterial, antiparasitic (leishmanicidal, trypanocidal, anthelmintic) and even anti-diabetic. Their structural versatility allows for modifications to enhance bioavailability, potency and selectivity against specific pathogens. Moreover, Mannich bases can target multiple biological pathways involved in the pathogenesis of NTDs and malaria, thereby offering a multifaceted approach to treatment. This review explores the pharmacological potential of Mannich bases in addressing NTDs and malaria.

Contemporary Developments in Ferrocene Chemistry: Physical, Chemical, Biological and Industrial Aspects

Ferrocenyl-based compounds have many applications in diverse scientific disciplines, including in polymer chemistry as redox dynamic polymers and dendrimers, in materials science as bioreceptors, and in pharmacology, biochemistry, electrochemistry, and nonlinear optics. Considering the horizon of ferrocene chemistry, we attempted to condense the neoteric advancements in the synthesis and applications of ferrocene derivatives reported in the literature from 2016 to date. This paper presents data on the progression of the synthesis of diverse classes of organic compounds having ferrocene scaffolds and recent developments in applications of ferrocene-based organometallic compounds, with a special focus on their biological, medicinal, bio-sensing, chemosensing, asymmetric catalysis, material, and industrial applications.

Design and synthesis of Mannich base-type derivatives containing imidazole and benzimidazole as lead compounds for drug discovery in Chagas Disease

The protozoan parasite Trypanosoma cruzi is the causative agent of Chagas disease, the most important parasitic infection in Latin America. The only treatments currently available are nitro-derivative drugs that are characterised by high toxicity and limited efficacy. Therefore, there is an urgent need for more effective, less toxic therapeutic agents. We have previously identified the potential for Mannich base derivatives as novel inhibitors of this parasite. To further explore this family of compounds, we synthesised a panel of 69 new analogues, based on multi-parametric structure-activity relationships, which allowed optimization of both anti-parasitic activity, physicochemical parameters and ADME properties. Additionally, we optimized our in vitro screening approaches against all three developmental forms of the parasite, allowing us to discard the least effective and trypanostatic derivatives at an early stage. We ultimately identified derivative 3c, which demonstrated excellent trypanocidal properties, and a synergistic mode of action against trypomastigotes in combination with the reference drug benznidazole. Both its druggability and low-cost production make this derivative a promising candidate for the preclinical, in vivo assays of the Chagas disease drug-discovery pipeline.

Chagas Disease Chemotherapy: What Do We Know So Far?

Chagas disease is a Neglected Tropical Disease (NTD), and although endemic in Latin America, affects around 6-7 million people infected worldwide. The treatment of Chagas disease is based on benznidazole and nifurtimox, which are the only available drugs. However, they are not effective during the chronic phase and cause several side effects. Furthermore, BZ promotes cure in 80% of the patients in the acute phase, but the cure rate drops to 20% in adults in the chronic phase of the disease. In this review, we present several studies published in the last six years, which describes the antiparasitic potential of distinct drugs, from the synthesis of new compounds aiming to target the parasite, as well as the repositioning and the combination of drugs. We highlight several compounds for having shown results that are equivalent or superior to BZ, which means that they should be further studied, either in vitro or in vivo. Furthermore, we stand out the differences in the effects of BZ on the same strain of T. cruzi, which might be related to methodological differences such as parasite and cell ratios, host cell type and the time of adding the drug. In addition, we discuss the wide variety of strains and also the cell types used as a host cell, which makes it difficult to compare the trypanocidal effect of the compounds.

Melnikov M, Zyk NV, Skvortsov DA, Lopatukhina EV, Vaneev AN, Gorelkin PV, Erofeev AS, Majouga AG, Beloglazkina EK. New Fe–Cu bimetallic coordination compounds based on ω-ferrocene carboxylic acids and 2-thioimidazol-4-ones: structural, mechanistic and biological studies

Synthesis, characterization and in vitro cytotoxic investigation of a series of new ferrocene-containing derivatives based on ω-ferrocene carboxylic acids and 2-alkylthioimidazolin-4-ones and their copper complexes have been reported.

Repositioning of leishmanicidal [1,2,3]Triazolo[1,5-a]pyridinium salts for Chagas disease treatment: Trypanosoma cruzi cell death involving mitochondrial membrane depolarisation and Fe-SOD inhibition

Trypanosomatidae is a family of unicellular parasites belonging to the phylum Euglenozoa, which are causative agents in high impact human diseases such as Leishmaniasis, Chagas disease and African sleeping sickness. The impact on human health and local economies, together with a lack of satisfactory chemotherapeutic treatments and effective vaccines, justifies stringent research efforts to search for new disease therapies. Here, we present in vitro trypanocidal activity data and mode of action data, repositioning leishmanicidal [1,2,3]Triazolo[1,5-a]pyridinium salts against Trypanosoma cruzi, the aetiological agent of Chagas disease. This disease is one of the most neglected tropical diseases and is a major public health issue in Central and South America. The disease affects approximately 6-7 million people and is widespread due to increased migratory movements. We screened a suite of leishmanicidal [1,2,3]Triazolo[1,5-a]pyridinium salt compounds, of which compounds 13, 20 and 21 were identified as trypanocidal drugs. These compounds caused cell death in a mitochondrion-dependent manner through a bioenergetic collapse. Moreover, compounds 13 and 20 showed a remarkable inhibition of iron superoxide dismutase activity of T. cruzi, a key enzyme in the protection from the damage produced by oxidative stress.